Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • Country/Region
    • Clinic Portal
      • +0034963905310
    • Request Information
    • +34 96 390 53 10
    • Part of brands: |
    InternationalInternational
    • Country/Region
      • Part of brands: |
      • We guide you
        • Fertility
          • What to do if…
        • Prevent Inherited Diseases
          • Carrier Genetic Test
        • Worry-free Pregnancy
          • NACE
          • Prenatal Diagnostics
          • Newborn Health
      • Reproductive Health
        • Specialists
          • ALICE
          • EMMA
          • ERA
          • EndomeTRIO
          • EMBRACE
          • CGT
          • NACE
          • Zenit
          • PGT-A
          • PGT-M
          • POC
          • SAT
          • Newborn Screening
        • Patients
          • ALICE
          • EMMA
          • ERA
          • EndomeTRIO
          • EMBRACE
          • CGT
          • NACE
          • Zenit
          • PGT-A
          • PGT-M
          • SAT
          • POC
      • Diagnostics
      • About us
        • Igenomix Research
        • About Igenomix
        • Igenomix Worldwide
      • Academy
      • Blog
      Genomics Precision Diagnostic > Oncology > Urologic Cancer Precision Panel

      Urologic Cancer Precision Panel

      The Igenomix Urologic Cancer Precision Panel has been designed to carry out an accurate and effective diagnosis of inherited cancers related to all the organs of the urologic system. It provides a comprehensive analysis of the most important cancer predisposition genes, including those associated with prostate cancer, kidney cancer and urothelial carcinoma (bladder, renal pelvis and ureter).
      Overview
      Indication
      Clinical Utility
      Genes & Diseases
      Methodology
      References

      Overview

      • Prostate cancer is one of the major causes of morbidity and mortality in men worldwide. Germline testing is a central feature of prostate cancer treatment, management, and hereditary cancer assessment. The percentage of patients with germline mutations in DNA repair genes ranges from 4.6% in localized disease to 11.8% to 16.2% in metastatic disease. Genetic results inform options and strategies for targeted treatment, therapeutic planning, and clinical trials in the metastatic setting. In addition, the identification of carriers of germline genetic variation associated with increased risk of prostate cancer enables targeted screening and early detection.

      • Hereditary renal cell carcinoma account for 5% to 8% of kidney cancers. There are several well-defined hereditary renal cell carcinoma syndromes, including von Hippel-Lindau disease, hereditary papillary renal cell carcinoma, hereditary leiomyomatosis and renal cell carcinoma, Birt-Hogg-Dubé syndrome, tuberous sclerosis, Cowden syndrome, microphthalmia associated transcription factor, and hereditary paraganglioma/pheochromocytoma. Although these syndromes have similarities, they vary in histology, aggressiveness, penetrance, and associated clinical manifestations. It is important to identify patients at risk for hereditary renal cell carcinoma, as it may influence care (e.g. partial versus radical nephrectomy and surveillance strategies) and optimize specific screening for family members at risk to enable early detection.

      • While the majority of urothelial carcinomas are chemically induced by smoking and occupational exposure to aromatic amines, mounting evidence from genetic studies have demonstrated a small, but consistent impact of inherited gene variants and family history in their development. Urothelial carcinomas are known component cancers of Lynch syndrome, which is caused by pathogenic variants in mismatch repair genes (MLH1, MSH2, MSH6, PMS2, and EPCAM). The role of germline testing for urothelial carcinoma has increased, with growing precision treatment implications and gene-specific management recommendations for carriers of germline variants related to increased risk of cancer.

      Indication

      The Igenomix Urologic Cancer Precision Panel is indicated in those cases where the physician is suspecting of a hereditary cancer syndrome. It is designed to diagnose adults with a personal or family history suggestive of inherited cancer in an organ of the urologic system, providing important information that may impact cancer treatment as well as cancer risk assessment and management.

      Clinical Utility

      The clinical utility of this panel is:  
       
      • Identify pathogenic cancer susceptibility variants
      • Maximize surveillance and preventive strategies for at risk individuals
      • Provide options and strategies for targeted treatment, therapeutic planning, and clinical trials
      • Perform risk assessment and genetic counselling for family members (cascade testing)

      Genes & Diseases

      Methodology

      References

      See scientific referrals

      Chang, D. W., Gu, J., & Wu, X. (2012). Germline prognostic markers for urinary bladder cancer: obstacles and opportunities. Urologic oncology, 30(4), 524–532. https://doi.org/10.1016/j.urolonc.2012.04.003

      Lenis, A. T., Lec, P. M., Chamie, K., & Mshs, M. D. (2020). Bladder Cancer: A Review. JAMA, 324(19), 1980–1991. https://doi.org/10.1001/jama.2020.17598

      Pandey J, Syed W. Renal Cancer. [Updated 2021 Dec 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK558975/

      Chang, A. J., Autio, K. A., Roach, M., 3rd, & Scher, H. I. (2014). High-risk prostate cancer-classification and therapy. Nature reviews. Clinical oncology, 11(6), 308–323. https://doi.org/10.1038/nrclinonc.2014.68

      Sokolova, A., & Cheng, H. (2021). Germline Testing in Prostate Cancer: When and Who to Test. Oncology (Williston Park, N.Y.), 35(10), 645–653. https://doi.org/10.46883/ONC.2021.3510.0645

      Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. Genetics in Medicine volume 22, pages709–718 (2020).

      Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. https://doi.org/10.1200/JCO.20.00046

      Germline and Somatic Mutations in Prostate Cancer for the Clinician J Natl Compr Canc Netw 2019;17(5):515–521 doi: 10.6004/jnccn.2019.7307

      Genetic Predisposition to Renal Cell Carcinoma: Implications for Counseling, Testing, Screening, and Management. J Clin Oncol 36:3560-3566. © 2018

      descargar

      Detail description

      Download

      Request Information


      WE GUIDE YOU

      Fertility
      Inherited diseases prevention
      Healthy pregnancy

      To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

      OUR SERVICES

      Genetic solutions
      For patients
      How to send a sample?
      User manual

      ABOUT US

      About Igenomix
      Contact
      Quality
      Complaints
      Work with us

      FOLLOW IGENOMIX

        + 96 390 53 10
        Write us
      • Argentina
      • Brazil
      • Canada
      • Chile
      • Colombia
      • Europe
      • France
      • Germany
      • India
      • Italy
      • Japan
      • Korea
      • Mexico
      • Perú
      • Russia
      • Spain
      • Taiwan
      • The Middle East
      • Turkey
      • United Kingdom
      • United States
      • Vietnam
      Country/Region

      [2021] © Igenomix Privacy policy Quality policy Legal note Cookies policyNews and Press

      Request Information

















      • We guide you
        • Fertility
          • What to do if…
        • Prevent Inherited Diseases
          • Carrier Genetic Test
        • Worry-free Pregnancy
          • NACE
          • Prenatal Diagnostics
          • Newborn Health
      • Reproductive Health
        • Specialists
          • ALICE
          • EMMA
          • ERA
          • EndomeTRIO
          • EMBRACE
          • CGT
          • NACE
          • Zenit
          • PGT-A
          • PGT-M
          • POC
          • SAT
          • Newborn Screening
        • Patients
          • ALICE
          • EMMA
          • ERA
          • EndomeTRIO
          • EMBRACE
          • CGT
          • NACE
          • Zenit
          • PGT-A
          • PGT-M
          • SAT
          • POC
      • Diagnostics
      • About us
        • Igenomix Research
        • About Igenomix
        • Igenomix Worldwide
      • Academy
      • Blog
      • Country/Region
      • +34 96 390 53 10
      • Clinic Portal
      • Request Information

      We are using cookies to give you the best experience on our website.

      You can find out more about which cookies we are using or switch them off in settings.

      International
      Powered by  GDPR Cookie Compliance
      Privacy Overview

      This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

      Strictly Necessary Cookies

      Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

      If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

      3rd Party Cookies

      This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

      Keeping this cookie enabled helps us to improve our website.

      Please enable Strictly Necessary Cookies first so that we can save your preferences!

      Cookie Policy

      More information about our Cookie Policy